bioRxivBioengineering
Fabrication of Molecular Blocks with High Responsiveness to the Cancer Microenvironment by Ursodeoxycholic Acid
Abstract
In cancer therapy, drug delivery system (DDS) has been widely studied to achieve selective drug accumulation at the tumor site. However, DDS still has a major drawback in that it requires multi-step processes for intracellular delivery, resulting in low efficiency of drug delivery. To overcome this problem, we recently reported a molecular block (MB) that disrupts cancer cell membranes in the cancer microenvironment using deoxycholic acid (DCA). However, the MB showed considerable cytotoxicity even at neutral pH possibly due to the structural hydrophobic property of DCA. Herein, we focused on selecting the most suitable bile acid for an MB that possessed high responsiveness to the cancer microenvironment without cytotoxicity at neutral pH. Cell viabilities of the free bile acids such as DCA, chenodeoxycholic acid (CDCA), cholic acid (CA) and ursodeoxycholic acid (UDCA) were evaluated at neutral pH (pH = 7.4) and a cancer acidic environment (pH = 6.3 [~] 6.5). The half-maximal inhibition concentration (IC50) value of UDCA at pH = 7.4 showed an approximately 7.5-fold higher IC50 value than that at pH = 6.3, whereas the other bile acids yielded less than a 4-fold IC50 value difference between the same pHs. Biocompatible poly(vinyl alcohol) (PVA) was functionalized with UDCA (PVA-UDCA) for synthesis of higher responsiveness to the cancer microenvironment without cytotoxicity at neutral pH. Importantly, 56% pancreatic cancer cell death was observed at pH = 6.5, whereas only 10% was detected at neutral pH by the PVA-UDCA treatment. However, PVA-DCA indicated almost the same cancer cell death property independent of pH condition. These results suggest PVA-UDCA shows great potential for a new class of MB.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Escape from Cell Uptake: Drug-Free Cancer Therapeutics Regulated Hydrophobicity and Negative Charge
Kazuki Moroishi, Masahiko Nakamoto, … Michiya Matsusaki·Materials Today BioPeer-reviewed·Dec 30, 2025
- Increasing Chemotherapeutic Efficacy Using pH Modulating and Doxorubicin Releasing Injectable Chitosan-Polyethylene Glycol Hydrogels
Z. Ahmed, K. LoGiudice, … V. Srivastava·bioRxiv·Jul 6, 2023
- Metabolic and Anti-Proliferative Responses of Pancreatic Cancer Cells to Ultrasound and Nanobubble Treatment
Sila Appak‐Baskoy, Muhammad Saad Khan, … Imogen R. Coe·bioRxiv·Apr 28, 2026
- Development and Characterization of Ultrasound-Activated Polymeric Microdroplets for Targeted Chemotherapy
Joshua Antonio Whiting, Audri Dara, … Jan Kubanek·International Journal of PharmaceuticsPeer-reviewed·Oct 7, 2026
- L-DOS47 enhances response to immunotherapy in pancreatic cancer tumor
B. V. Jardim-Perassi, P. Irrera, … A. Ibrahim-Hashim·bioRxiv·Aug 28, 2023
- ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1
J. Rincon-Torroella, M. Dal Molin, … S. Sur·bioRxiv·Jul 23, 2023